Elan Myobloc Could Launch Ahead Of Botox Approval For Cervical Dystonia
Executive Summary
Elan's plans to launch its neurotoxin Myobloc for cervical dystonia in early January may allow it some time on the market before Allergan's anticipated approval of Botox for the same indication.